Transforming gene therapy through the discovery and detection of complex genetic changes
Direct, Definitive Genomics
single-cell innovative solutions for the discovery, evaluation, and characterization of gene editing, chromosomal rearrangements, and structural variations for cell and gene therapy scientists
Products
detect mutations, chromosomal rearrangements and structural variations with robust signals, and a genome wide perspective using dGH™ and Pinpoint FISH™ probes
Services
receive superior detection and quantifiable evaluation data using our robust dGH™ and Pinpoint FISH™ assay services and world class quality control
Applications
products and assay solutions for applications using cell and gene therapy, gene editing, oncology studies, and radiation biodosimetry
KromaTiD News
Company News + Press
- KromaTiD Announces Launch of dGH Cell Prep Kit
- KromaTiD Announces Launch of Pinpoint FISH™ DNA Probes
- Just Up on the Blog! KromaTiD’s Dark Lab Files: The Great Race to Cure Cancer – CAR-T Segment
- Register for KromaTiD’s directional Genomic Hybridization™ Webinar Featured on GEN News April 27th
- Just Up on the Blog! KromaTiD’s Dark Lab Files: Cytogenetics a Little History Lesson
- KromaTiD Announces Launch of Cell Culture Services
- KromaTiD Announces EARLY ACCESS Launch of TP53/CEP17 Kit for Synthetic Oligonucleotide-Based FISH Assay
- KromaTiD Announces Launch of dGH SCREEN™
- Applied Spectral Imaging and KromaTiD announce strategic commercial partnership
- KromaTiD and dGH in-Site featured in Genetic Engineering & Biotechnology News
Videos, Presentations & Webinars
- KromaTiD Webinar dGH SCREEN October 4, 2022 REGISTER TODAY!
- KromaTiD Webinar CRISPR Off Target Gene Editing (GEN News)
- KromaTiD Presents at Next Gen Omics Boston
- KromaTiD’s Cell Culture Services Protocol
- Dr. Chris Tompkins and Erin Cross present webinar for the launch of dGH SCREEN™ for unbiased whole genome analysis of chromosomal structural rearrangements
- Dr. Lauren Kinner-Bibeau presents webinar on single-cell measurements of genomic inserts and transgenes
- KromaTiD presents at the 2020 virtual NextGen Omics Series
- KromaTiD CTO Dr. Chris Tompkins presents at the 2020 Cell & Gene Therapy Virtual Congress
Market News
- Bluebird on a Roll with Second FDA Approval in Matter of Weeks
- Intellia’s Latest Data Indicates Full Potential of CRISPR
- Guardant, Merck KGaA expand precision therapeutics collab, focusing on hard-to-treat cancer
- J&J bags first nod for multiple myeloma bispecific to complement its own CAR-T offering
- Eagle swoops down to nab chunk of BARDA-backed Enalare Therapeutics
- Looking east, Sanofi pens ‘pioneering’ cancer drug partnership with China’s Innovent
- Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
- Verve Starts First Human Test of Gene Editing Treatment for Heart Disease
- BMS Takes CAR-T Patent Case to Top Court in Bid to Revise $2.1B Verdict Against Gilead